Program
nintedanib
Also written as “Nintedanib”, “BIBF 1120” and “Nintedanib (BIBF1120)”.
Its studies are mostly in Idiopathic Pulmonary Fibrosis · Carcinoma, Non-Small-Cell Lung · Pulmonary Fibrosis · Lung Diseases, Interstitial · Neoplasms, led by 3 companies.
Drug pageNintedanib: every studyAll 141 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheimits history only | 620 open or running | phase 4since Oct 16, 2015 | Aug 9, 2007 | none ahead |
| Mannkind | 10 open or running | phase 1since Jan 7, 2026 | Jan 7, 2026 | none ahead |
| PureTechits history only | 10 open or running | phase 1since Nov 20, 2024 | Nov 20, 2024 | none ahead |
Also a collaborator on its studies: Novotech (Australia) Pty and Parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Mannkind only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 7, 2026First study: phase 1 study in Idiopathic Pulmonary FibrosisFirst studyNCT07344558 · 27 enrolled · United States
TargetBeta
“Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor; Fibroblast growth factor receptor inhibitor”ChEMBL 37, by rule
Studies
The one study Mannkind leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07344558Idiopathic Pulmonary Fibrosis · United States | 1 | Completed | Jun 17, 2026 | 27 |
How it is read
Names in the registry
- “Nintedanib”, 43 entries
- “BIBF 1120”, 26 entries
- “nintedanib”, 4 entries
- “Nintedanib (BIBF1120)”, 2 entries
- “Nintedanib high dose”, 2 entries
Codes read as this program: MNKD201.
Conditions, from the studies’ own filings
- Idiopathic Pulmonary Fibrosis, 13 studies
- Carcinoma, Non-Small-Cell Lung, 10 studies
- Pulmonary Fibrosis, 6 studies
- Lung Diseases, Interstitial, 6 studies
- Neoplasms, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.